Lateral Flow Assays Market in terms of revenue was estimated to be worth $20.5 billion in 2022 and is poised to reach $22.6 billion by 2027, growing at a CAGR of 2.0% from 2022 to 2027 according to a new report by MarketsandMarkets™. The increasing demand of lateral flow assays due to increase in prevalence of infectious disease, increasing number of geriatric populations in many countries, and rising use of home-based lateral flow assay devices are the major factors driving the growth of this market. On the other hand, reluctance among doctors and patients to change existing diagnostic procedures and the low accuracy of lateral flow assays are the key restraints.
Download an Illustrative overview:
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=167205133
Browse in-depth TOC on "Kits Lateral Flow Assays Market"
366 - Tables
58 - Figures
374 - Pages
In this report, the lateral flow assays market is segmented on the basis of product type, application type, technique type, sample type, end user, and region.
"Lateral Flow Readers segment is expected to witness the fastest growth during the forecast period"
Based on product type, the lateral flow assays market is segmented into kits & reagents and lateral flow readers. During the forecast period, this segment is expected to witness the fastest growth during the forecast period. The factors responsible for the growth of this segment are increasing demand of quantitative analysis of clinical sample.
"Veterinary Diagnostics segment accounted for the second largest share of Readers lateral flow assays industry in 2021"
Based on applications, the lateral flow assays market is segmented into clinical testing, veterinary diagnostics, food safety & environmental testing, and drug development & quality testing. The veterinary diagnostics segment accounted for the second largest share of the lateral flow assays market in 2021. The possibility of infectious disease outbreaks (particularly in large livestock animals) is driving the demand for lateral flow tests due to their simplicity and rapidity compared to conventional detection methods.
"Multiplex Detection Assays technique is expected to witness the fastest growth during the forecast period"
Based on technique, the lateral flow assay kits & reagents market is segmented into competitive assays, sandwich assays, and multiplex detection assays. The multiplex detection assays technique is expected to witness the fastest growth during the forecast period. The widening scope, applications, and research on multiplex detection assays are expected to boost the growth of this segment in the forecast period.
The lateral flow assays market is segmented into five regions namely North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Asia-Pacific is the second largest region along with fastest growing region of lateral flow assays market owing to major investments in rapid testing in this region.
Request for FREE Sample Pages:
https://www.marketsandmarkets.com/requestsampleNew.asp?id=167205133
Lateral Flow Assays Market Dynamics:
Drivers:
- High prevalence of infectious diseases across the globe
- Rapidly increasing geriatric population
- Growing usage of home-based lateral flow assay devices
- Growing demand for point-of-care testing
- Need for rapid diagnostic testing for COVID-19
Restraints:
- Inconsistent results of lateral flow assay tests
Opportunities:
- Evolving applications of lateral flow assays
- Rising demand for lateral flow assays in the food & beverage industry
- Omicron – The new variant of concern is an opportunity for the lateral flow assays market
- Government initiatives for omicron
- Initiatives of Medical diagnostic companies for omicron
Challenges:
- Limited reimbursements for lateral flow assay products
- Difficulties in procuring quality raw materials for the development of lateral flow assay tests
Key Market Players:
The prominent players in the global lateral flow assays market include Abbott Laboratories (US), Quidel Corporation (US), F. Hoffman-La Roche AG (Switzerland), Danaher Corporation (US), Siemens AG (Germany), BD (US), bioMérieux SA (France), Thermo Fisher Scientific, Inc. (US), PerkinElmer Inc. (US), Hologic Inc. (US), QIAGEN N.V. (Netherlands), and Merck KGaA (Germany).
Abbott Laboratories, Inc.
Abbott Laboratories accounted for an estimated share of 33–36% of the lateral flow assays market in 2021. Abbott is leading player in this market due its strong organic and inorganic strategies such as, the company focuses on expanding and strengthening its partnerships with existing customers, enhancing operations and quality, and enhancing product scope, capabilities, and expertise.
- Hoffmann-La Roche AG
- Hoffmann-La Roche Ltd. accounted for an estimated share of 8–10% of the lateral flow assays market in 2021. Roche has strong portfolio in clinical segments for screening of multiple infectious diseases. Also company has strong investments in R&D.
Becton, Dickinson and Company
Becton, Dickinson and Company accounted for an estimated share of 7–9% of the lateral flow assays market in 2021. The company’s diagnostics product portfolio focuses on rapid tests for infectious diseases through investments in the form of partnerships and collaborations. For instance, in April 2021, the company partnered with USA Track & Field (USATF) (US) to provide rapid COVID-19 testing for USATF athletes at Journey to Gold through the use of the BD Veritor Plus System.
Recent Developments:
- In October 2022, F. Hoffmann-La Roche Ltd. (Switzerland) a next-generation portfolio of SARS-CoV-2 rapid antigen test 2.01, SARS-CoV-2 Rapid Antigen Test 2.0 Nasal2, and SARS-CoV-2 Rapid Antigen Test 2.0 Nasal3
- In June 2021, Abbott Laboratories (US) received the CE approval for PanBio Rapid Antigen Self-test, opening access throughout Europe to fast, reliable COVID-19 testing
Get 10% Free Customization on this Report:
https://www.marketsandmarkets.com/requestCustomizationNew.asp?id=167205133
Lateral Flow Assays Market - Report Highlights:
Refinements in the segments of the lateral flow assays market
The current edition of the report consists of an updated market overview. Additional points in the market overview have been added, keeping in mind the impact of COVID-19 on the overall lateral flow assays market and economic recession impact on lateral flow assays market. Also impact of economic recession on regional market size has been considered in this edition.
Coverage of new market players in the lateral flow assays market
The new edition of the report includes profiles for Oranoxis Inc. (US), AESKU. Diagnostics Gmbh (Germany), Bio Group Medical System (Italy), Pharmact Gmbh (Germany), DIESSE Diagnostica Senese S.P.A (Italy), and Xiamen Biotime Biotechnology Co., Ltd (China).
Updated financial information/product portfolio of players
The new edition of the report provides updated financial information until 2021 for each listed company in a graphical representation as a single diagram (instead of multiple tables). This will easily help analyze the present status of profiled companies in terms of their financial strength, profitability, key revenue-generating country/region, business segment focus in terms of the highest revenue-generating segment, and R&D investments.
Updated market developments of profiled players
Recent developments are important to understand market trends and the growth strategies adopted by players. The current edition of this report provides updated developments of profiled players from January 2019 to December 2022, indicating a continuation from the previous version. Product/services launches, approvals, and upgrades, expansions, acquisitions, agreements, partnerships, and collaborations were the principal growth strategies adopted by market players in this period.
About MarketsandMarkets™:
MarketsandMarkets™ has been recognized as one of America's best management consulting firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. We have the widest lens on emerging technologies, making us proficient in co-creating supernormal growth for clients.
Earlier this year, we made a formal transformation into one of America's best management consulting firms as per a survey conducted by Forbes.
The B2B economy is witnessing the emergence of $25 trillion of new revenue streams that are substituting existing revenue streams in this decade alone. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines - TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we work with several Forbes Global 2000 B2B companies - helping them stay relevant in a disruptive ecosystem. Our insights and strategies are molded by our industry experts, cutting-edge AI-powered Market Intelligence Cloud, and years of research. The KnowledgeStore™ (our Market Intelligence Cloud) integrates our research, facilitates an analysis of interconnections through a set of applications, helping clients look at the entire ecosystem and understand the revenue shifts happening in their industry.
Contact:
Mr. Aashish Mehra
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com
Research Insight: https://www.marketsandmarkets.com/ResearchInsight/lateral-flow-assay-market.asp
Content Source: https://www.marketsandmarkets.com/PressReleases/lateral-flow-assay.asp